Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 5/2018

Ausgabe 5/2018

Inhaltsverzeichnis ( 25 Artikel )

16.01.2018 | PRECLINICAL STUDIES | Ausgabe 5/2018

Sphingadienes show therapeutic efficacy in neuroblastoma in vitro and in vivo by targeting the AKT signaling pathway

Piming Zhao, Ana E. Aguilar, Joanna Y. Lee, Lucy A. Paul, Jung H. Suh, Latika Puri, Meng Zhang, Jennifer Beckstead, Andrzej Witkowski, Robert O. Ryan, Julie D. Saba

08.01.2018 | PRECLINICAL STUDIES | Ausgabe 5/2018

The in vitro assessment of dipyridophenazine complexes in H-ras oncogene transformed rat embryo fibroblast 5RP7 cell line

Ayse Kaplan, Kadriye Benkli, Ayse Tansu Koparal

05.03.2018 | PRECLINICAL STUDIES | Ausgabe 5/2018

PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation

Songlin Liu, Yunhong Tang, Maomao Yan, Weixi Jiang

31.01.2018 | PRECLINICAL STUDIES | Ausgabe 5/2018

SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy

Michael I. Koukourakis, Alexandra Giatromanolaki, Konstantina Fylaktakidou, Efthimios Sivridis, Christos E. Zois, Dimitra Kalamida, Achilleas Mitrakas, Stamatia Pouliliou, Ilias V. Karagounis, Konstantinos Simopoulos, David J. P. Ferguson, Adrian L. Harris

02.02.2018 | PRECLINICAL STUDIES | Ausgabe 5/2018

Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes

Maria Eduarda Azambuja Amaral, Laura Roesler Nery, Carlos Eduardo Leite, Walter Filgueira de Azevedo Junior, Maria Martha Campos

14.02.2018 | PRECLINICAL STUDIES | Ausgabe 5/2018 Open Access

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide

Ruud Oerlemans, Celia R. Berkers, Yehuda G. Assaraf, George L. Scheffer, Godefridus J. Peters, Sue Ellen Verbrugge, Jacqueline Cloos, Jerry Slootstra, Rob H. Meloen, Robert H. Shoemaker, Ben A. C. Dijkmans, Rik J. Scheper, Huib Ovaa, Gerrit Jansen

02.03.2018 | PRECLINICAL STUDIES | Ausgabe 5/2018

Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor

Staci L. Haney, Yashpal S. Chhonker, Michelle L. Varney, Geoffrey Talmon, Daryl J. Murry, Sarah A. Holstein

20.02.2018 | PRECLINICAL STUDIES | Ausgabe 5/2018 Open Access

The concomitant use of lapatinib and paracetamol - the risk of interaction

Agnieszka Karbownik, Edyta Szałek, Katarzyna Sobańska, Tomasz Grabowski, Agnieszka Klupczynska, Szymon Plewa, Anna Wolc, Magdalena Magiera, Joanna Porażka, Zenon J. Kokot, Edmund Grześkowiak

08.01.2018 | PHASE I STUDIES | Ausgabe 5/2018 Open Access

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

Diane A. J. van der Biessen, Jourik A. Gietema, Maja J. A. de Jonge, Ingrid M. E. Desar, Martha W. den Hollander, Matthew Dudley, Martin Dunbar, Robert Hetman, Camille Serpenti, Hao Xiong, Rajendar K. Mittapalli, Kirsten M. Timms, Peter Ansell, Christine K. Ratajczak, Stacie Peacock Shepherd, Carla M. L. van Herpen

15.01.2018 | PHASE I STUDIES | Ausgabe 5/2018

A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors

Gentry T. King, Keith D. Eaton, Brandon R. Beagle, Christopher J. Zopf, Gilbert Y. Wong, Heike I. Krupka, Steven Y. Hua, Wells A. Messersmith, Anthony B. El-Khoueiry

19.01.2018 | PHASE I STUDIES | Ausgabe 5/2018 Open Access

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

Andreas Schneeweiss, Tjoung-Won Park-Simon, Joan Albanell, Ulrik Lassen, Javier Cortés, Veronique Dieras, Marcus May, Christoph Schindler, Frederik Marmé, Juan Miguel Cejalvo, Maria Martinez-Garcia, Iria Gonzalez, Jose Lopez-Martin, Anja Welt, Christelle Levy, Florence Joly, Francesca Michielin, Wolfgang Jacob, Céline Adessi, Annie Moisan, Georgina Meneses-Lorente, Tomas Racek, Ian James, Maurizio Ceppi, Max Hasmann, Martin Weisser, Andrés Cervantes

29.01.2018 | PHASE I STUDIES | Ausgabe 5/2018

First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors

Vicki L. Keedy, Heinz-Josef Lenz, Leonard Saltz, Jennifer G. Whisenant, Jordan D. Berlin, Luis H. Camacho

17.02.2018 | PHASE I STUDIES | Ausgabe 5/2018 Open Access

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study

Anastasios Stathis, Ian W. Flinn, Sumit Madan, Kami Maddocks, Arnold Freedman, Steven Weitman, Emanuele Zucca, Mihaela C. Munteanu, M. Lia Palomba

09.03.2018 | PHASE I STUDIES | Ausgabe 5/2018

Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy

Hyungwoo Cho, Dok Hyun Yoon, Kyu-pyo Kim, Kyun-Seop Bae, Won Seog Kim, Hyeon-Seok Eom, Jin Seok Kim, Jung Yong Hong, Seok Jin Kim, Hyewon Lee, Soo-Jeong Kim, Cheolwon Suh

16.05.2018 | PHASE I STUDIES | Ausgabe 5/2018

A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers

Aflah Roohullah, Adam Cooper, Anna J. Lomax, Jennifer Aung, Alan Barge, Lilian Chow, Mark McHale, Jayesh Desai, James R. Whittle, Ben Tran, Paul de Souza, Lisa G. Horvath

13.06.2018 | PHASE II STUDIES | Ausgabe 5/2018

Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer

Amir Mehrvarz Sarshekeh, Henry Q. Xiong, Kenzo Iizuka, Howard S. Hochster, Scott Kopetz

30.05.2018 | PHASE II STUDIES | Ausgabe 5/2018

Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial

Akira Nakao, Junji Uchino, Fumiyasu Igata, Rintaro On, Takato Ikeda, Hiroshi Yatsugi, Ryosuke Hirano, Tomoya Sasaki, Keiko Tanimura, Tatsuya Imabayashi, Nobuyo Tamiya, Yoshiko Kaneko, Tadaaki Yamada, Nobuhiko Nagata, Kentaro Watanabe, Junji Kishimoto, Koichi Takayama, Masaki Fujita

13.06.2018 | PHASE II STUDIES | Ausgabe 5/2018

Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: a prospective study

Cassia Regina Guedes Leal, Cristiane Magalhães, Daniel Barbosa, Diogo Aquino, Bernardo Carvalho, Elizabeth Balbi, Lucio Pacheco, Renata Perez, Paulo de Tarso Pinto, Sérgio Setubal

07.08.2018 | PHASE II STUDIES | Ausgabe 5/2018 Open Access

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Paul Monk, Glenn Liu, Walter M. Stadler, Susan Geyer, Ying Huang, John Wright, Miguel Villalona-Calero, James Wade, Russell Szmulewitz, Shilpa Gupta, Amir Mortazavi, Robert Dreicer, Roberto Pili, Nancy Dawson, Saby George, Jorge A. Garcia

28.06.2018 | PHASE II STUDIES | Ausgabe 5/2018

Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world

Felice Pasini, Carmen Barile, Donatella Caruso, Yasmina Modena, Anna Paola Fraccon, Laura Bertolaso, Daniela Menon, Francesca La Russa, Giorgio Crepaldi, Antonio Bononi, Roberto Spezzano, Roberto Padrini, Giuseppe Corona, Milena Gusella

13.12.2017 | REVIEW | Ausgabe 5/2018

Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database

D. Shepshelovich, H. Goldvaser, L. Wang, A. R. Abdul Razak

23.03.2018 | REVIEW | Ausgabe 5/2018

Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis

Akiyoshi Kasuga, Yasuo Hamamoto, Ayano Takeuchi, Naohiro Okano, Kazuhiro Togasaki, Yu Aoki, Takeshi Suzuki, Kenta Kawasaki, Kenro Hirata, Yasutaka Sukawa, Takanori Kanai, Hiromasa Takaishi

02.05.2018 | SHORT REPORT | Ausgabe 5/2018

Crizotinib-induced simultaneous multiple cardiac toxicities

Takuya Oyakawa, Nao Muraoka, Kei Iida, Masatoshi Kusuhara, Takahisa Kawamura, Tateaki Naito, Toshiaki Takahashi

02.05.2018 | SHORT REPORT | Ausgabe 5/2018

Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report

Ryosuke Hirabayashi, Daichi Fujimoto, Yukari Satsuma, Masaki Hirabatake, Keisuke Tomii

31.05.2018 | SHORT REPORT | Ausgabe 5/2018

GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death

Juliana Carvalho Alves-Silva, Juliana Lott de Carvalho, Doralina Amaral Rabello, Teresa Raquel Tavares Serejo, Eduardo Magalhaes Rego, Francisco Assis Rocha Neves, Antonio Roberto Lucena-Araujo, Fábio Pittella-Silva, Felipe Saldanha-Araujo

Aktuelle Ausgaben


 

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise